Search research articles
Contact Us
Filters
Showing results (181-190 of 264) with videos related to
Page
of 27
Sort By:
The New England Journal of Medicine
|
June 16, 2006
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz, Neil P Shah, Hagop Kantarjian, et al.
British Journal of Haematology
|
April 3, 2004
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome
Maha M T El-Zimaity, Hagop Kantarjian, Moshe Talpaz, et al.
American Journal of Hematology
|
March 5, 2020
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 22, 2009
Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate
David A Dorr, Rachel Burdon, Dennis P West, et al.
ACS Pharmacology & Translational Science
|
September 19, 2025
Understanding the Functional Dependence and Inhibition of the Bcl‑2 Pro-Survival Proteins in a Wide Spectrum of Cancers toward Precision Medicine
Karson J Kump, Ejaz Ahmad, Charles Foucar, et al.
The Lancet. Haematology
|
June 13, 2017
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Haematologica
|
January 25, 2024
A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial
Srdan Verstovsek, Moshe Talpaz, Martha Wadleigh, et al.
The Lancet. Haematology
|
September 12, 2024
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial
Claire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
Leukemia & Lymphoma
|
June 5, 2024
Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial
Vikas Gupta, Abdulraheem Yacoub, Ruben A Mesa, et al.
Bioorganic & Medicinal Chemistry
|
January 25, 2014
Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I)
Zhenghong Peng, David S Maxwell, Duoli Sun, et al.
Page
of 27
Search research articles
Search
Showing results (181-190 of 264) with videos related to
Sort By:
Page
of 27
The New England Journal of Medicine
|
June 16, 2006
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz, Neil P Shah, Hagop Kantarjian, et al.
British Journal of Haematology
|
April 3, 2004
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome
Maha M T El-Zimaity, Hagop Kantarjian, Moshe Talpaz, et al.
American Journal of Hematology
|
March 5, 2020
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 22, 2009
Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate
David A Dorr, Rachel Burdon, Dennis P West, et al.
ACS Pharmacology & Translational Science
|
September 19, 2025
Understanding the Functional Dependence and Inhibition of the Bcl‑2 Pro-Survival Proteins in a Wide Spectrum of Cancers toward Precision Medicine
Karson J Kump, Ejaz Ahmad, Charles Foucar, et al.
The Lancet. Haematology
|
June 13, 2017
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Haematologica
|
January 25, 2024
A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trial
Srdan Verstovsek, Moshe Talpaz, Martha Wadleigh, et al.
The Lancet. Haematology
|
September 12, 2024
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial
Claire N Harrison, Ruben Mesa, Moshe Talpaz, et al.
Leukemia & Lymphoma
|
June 5, 2024
Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial
Vikas Gupta, Abdulraheem Yacoub, Ruben A Mesa, et al.
Bioorganic & Medicinal Chemistry
|
January 25, 2014
Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I)
Zhenghong Peng, David S Maxwell, Duoli Sun, et al.
Page
of 27